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age peak in the 6th and 7th decades of life  [1] . The fre-
quency of multicentricity lies between 26 and 30%  [3, 4] 
and 15–29% of tumors are associated with other non-car-
cinoid malignancies  [5–7] . The WHO classification sub-
divides jejunal-ileal tumors, similar to other gastroen -
 teropancreatic endocrine tumors, into three general cat-
egories  [8] : (1) well-differentiated endocrine tumor 
(carcinoid) of benign behavior (confined to the mucosa-
submucosa, non-angioinvasive,  ! 1 cm in size) or uncer-
tain behavior (non-functioning, confined to mucosa-
submucosa,  1 1 cm in size, or angioinvasive); (2) well-dif-
ferentiated endocrine carcinoma (malignant carcinoma) 
with low-grade malignant behavior, deeply invasive 
(muscularis propria or beyond) or with metastases, and 
(3) poorly-differentiated endocrine carcinoma (small-cell 
carcinoma), high-grade malignant.
 Introduction
 Epidemiology and Clinicopathological Features
 Neuroendocrine tumors of the lower jejunum and il-
eum account for 23–28% of all gastrointestinal endocrine 
tumors and incidence rates of 0.28–0.8 per 100,000 pop-
ulation per year have been reported  [1, 2] . Most of these 
tumors are well-differentiated and have an indolent 
course. As a consequence of the long delay between onset 
of symptoms and final diagnosis, many patients have ad-
vanced disease at the time of diagnosis. These tumors oc-
cur with equal frequency in males and females with an 
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 Minimal Consensus Statement on Clinical 
Presentation
 
 The consensus was that the rate of functionality and presence 
of the carcinoid syndrome in this patient group is about 20–30%, 
i.e. higher than previously stated. It was also stressed that small 
bowel ischemia could be another cause of diarrhea and pain be-
sides hormone-related diarrhea. In the literature, flushing is re-
ported to be a more frequent presenting symptom (in 90% of 
patients with the carcinoid syndrome) than diarrhea (80%), but 
according to clinical experience the rate is roughly the same. It 
was emphasized the atypical carcinoid syndrome due to hista-
mine by persecretion is not seen in midgut jejunal-ileal endo-
crine tumors. The carcinoid syndrome is usually seen in patients 
with liver metastases (in 95% of patients), but excess tachykinin-
serotonin production from retroperitoneal metastases or ovar-
ian tumors/metastases can bypass the liver and enter the sys-
temic circulation and cause the typical carcinoid syndrome (in 
5% of patients).
 Prognosis
 The prognosis of tumors of the jejunum-ileum is gen-
erally unfavorable if compared to that of other gastroin-
testinal endocrine tumors, since they have a tendency to 
spread via regional lymph nodes to the liver  [3, 10] . Sur-
vival of endocrine jejunal-ileal tumors correlates closely 
with the stage of the disease at presentation with a 5-year 
survival of 65% in patients with localized or regional dis-
ease and 36% in those with distant metastases  [1, 3, 10, 
12] . Patients with slow-growing well-differentiated tu-
mors and those with a low Ki-67 live longer than those 
with a more rapidly growing well-differentiated with a 
high Ki-67  [13] .
 Minimal Consensus Statement on Prognosis
 
 In contrast to other gastrointestinal endocrine tumors, tu-
mors of the jejunum-ileum of comparable size can behave very 
aggressively  [14] . According to the literature, only 23% of pa-
tients having undergone apparently curative resection were free 
of disease after 25 years  [15] . Regional lymph node metastases 
are present at the time of diagnosis in 36–39% and non-localized 
disease is evident in 64.1% of the patients  [1] . For localized tu-
mors of the small intestine, the 5-year survival rate is 65–75%  [1, 
7, 16] ; for regional disease the corresponding figure is 64–73% 
 [1] , whereas for non-localized tumors the 5-year survival is 50% 
according to the SEER registry  [1] . The 5-year survival rate of 
patients with hepatic tumor spread is 18–32%  [1, 7, 10] . If all stag-
es are combined, the 5-year survival rate of neuroendocrine tu-
mors of jejunum-ileum is 60.5%  [1] . Whether extensive disease 
leads to poorer survival is not known but the presence of the car-
cinoid syndrome has been described to decrease survival. The 
5-year survival in these patients is 21%  [17] , and the median sur-
vival is 38 months from the first flush and 23 months from the 
detection of elevated urinary 5-hydroxyindoleacetic acid  [18] .
 
 Minimal Consensus Statement on Epidemiology and 
Clinicopathological Features
 
 The clinical incidence for small intestinal endocrine tumors 
is considerably lower than the incidence at autopsy (1/150)  [9] . 
Clinical incidence is probably higher than stated earlier in the 
literature. The incidence for jejunal-ileal tumors in the pan-
SEER registry (1973–1999) is 26% among gastrointestinal carci-
noids  [1] . The average age at diagnosis for patients with small 
intestinal carcinoids is 65.4 years and comparison of registries 
suggests an overall increase in the average age at diagnosis  [1] . 
According to the literature there is no gender preference, where-
as there are some racial differences. Black Americans have a 
slightly higher risk than Caucasians (1.09 corrected ratio) of de-
veloping jejunal-ileal tumors.
 Clinical Presentation
 Non-Functioning Tumors. Asymptomatic endocrine 
tumors in the distal small intestine are discovered while 
searching for a primary in patients with newly discovered 
liver metastases from an endocrine tumor or incidentally 
during colonoscopy or intubation of the terminal ileum. 
At the time of diagnosis, the tumors are commonly
 1 2 cm and have invaded the muscularis propria and also 
metastasized to regional lymph nodes. Typical symptoms 
include intermittent abdominal discomfort misinter-
preted as irritable bowel disease for many years. Peritu-
moral fibrosis can lead to intestinal obstruction and by 
adhesions of intestinal loops or luminal stricture, which 
may lead to ileus  [10] . Some patients may develop non-
secretory diarrhea due to bacterial overgrowth. Further-
more, fibrosis around mesenteric metastases can cause 
fixation of the ileal mesentery to the retroperitoneum 
with fibrous bands obstructing the small intestine and 
transverse colon. This desmoplastic reaction may culmi-
nate in small bowel ischemia or hydronephrosis.
 Functioning Tumors. Up to 18% of patients with liver 
metastases due to an endocrine tumor of the jejunum-il-
eum present the carcinoid syndrome  [11] . Signs and 
symptoms of the carcinoid syndrome can include one or 
any of the following: flushing, diarrhea, carcinoid heart 
disease (CHD), and intermittent bronchoconstriction. 
Abdominal pain due to the desmoplastic reaction sur-
rounding the primary and mesenteric lymph node me-
tastases can also be present in these patients.
 Carcinoid crisis is a severe and potentially fatal exac-
erbation of hormonal symptoms often provoked by anes-
thesia or invasive procedures, such as surgery. The clini-
cal picture includes flushing, hypo- or hypertension, di-
arrhea, severe bronchospasm and cardiac arrhythmias.
 Eriksson  et al.
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 The prevalence of CHD in patients with the carcinoid 
syndrome is 30–65%  [19, 20] . Right-sided heart failure, 
caused by CHD rather than tumor progression, was the 
cause of death in 30–50% of patients  [19–21] . Besides high 
age and elevated 5-HIAA levels, tricuspid regurgitation 
was the most significant predictor of death  [22] .
 Even though the age at diagnosis did not decrease, the 
survival rates among these patients are improving, which 
may be attributed to a multimodal approach with more 
aggressive surgery with removal of primary tumors and 
solitary liver metastases, medical therapy, and other new 
therapeutic options. The application of a new Tumor 
Node Metastases (TNM) classification for small intesti-
nal endocrine tumors should prove to be an important 
prognostic tool and within the new classification, it may 
be prognostically valuable to distinguish between differ-
ent M-stages.
 Diagnostic Procedures ( fig. 1 )
 Imaging
 The standard imaging procedures for endocrine tu-
mors of the lower jejunum-ileum include abdominal ul-
trasonography, contrast-enhanced helical CT or MRI of 
the abdomen in combination with somatostatin receptor 
scintigraphy (SRS), endoscopy, echocardiography, bone 
scan or spine MRI to prove bone metastases if SRS is neg-
ative.
 In most patients with a metastasized jejunal-ileal car-
cinoid, transabdominal ultrasonography is the initial im-
aging procedure disclosing the presence of liver metasta-
ses. The technique is operator-dependent. Sensitivity and 
specificity have been variable. New contrast media have 
improved sensitivity and specificity (around 95%). Ultra-
sound may be used to guide percutaneous coarse-needle 
biopsies for histopathological diagnosis (flowchart in 
 fig. 1 ).
Diagnosis and staging:
lower jejunal and ileal tumor Abdominal US
Liver
metastases 
Primary and
metastases 
Abdominal
lesions
Bone
leisions
No primary 
Histopathological
diagnosis: NET
SRS (SPECT)
SPECT-CT
3-Phase CT
MRI
MRI
Bone
scintigraphy 
68Ga-DOTA-
octreotide-PET
Colonoscopy
Double balloon 
enteroscopy
Capsule endoscopy
Echocardiography !
Biochemistry
CgA
5-HIAA
 Fig. 1.  Diagnostic algorithm for jejunal-
ileal tumors. 
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 Minimal Consensus Statement on Imaging
 
 In the search for a primary tumor, colonoscopy should be 
performed particularly in the context of synchronous neoplastic 
disease. Double balloon enteroscopy will probably have a role in 
the future but the method needs further validation. Capsule en-
doscopy can be useful after enteroclysm has failed to detect the 
intestinal primary tumor(s). Capsule endoscopy has a similar 
diagnostic yield as SRS and the advantage of being able to dif-
ferentiate between intestinal and mesenterial localization  [30, 
31] . Endoscopic ultrasonography, on the other hand, has no 
place in this setting.
 
 
 Fusion imaging with SRS plus SPECT/CT is preferred 
since it provides a more accurate morphological localiza-
tion. If SRS is negative,  18 F-DOPA-PET or  11 C-5-HTP-
PET may be considered.  68 Ga-DOTA-octreotide-PET, 
which does not require an in-house cyclotron, is (not yet 
for sale/approved by EMEA/FDA; similar to the other 
PET agents except FDG), however, accessible in very few 
research centers, and has been demonstrated to detect 
30% more lesions than SRS  [24] .
 Laboratory Tests
 A specific constellation of symptoms should be fol-
lowed up by performance of specific biochemical tests. 
Chromogranin A may serve as a sensitive marker in func-
tioning and non-functioning tumors of the jejunum-ile-
um. However, its specificity is rather low in midgut neu-
roendocrine tumors. There is a correlation between the 
chromogranin A levels and prognosis  [32] . It should be 
mentioned that available assays for chromogranin A dif-
fer in sensitivity due to different antibody specificities 
 [33] . Endocrine tumors of the jejunum-ileum produce se-
rotonin and elevated 24-hour urinary 5-HIAA levels. 5-
HIAA has a sensitivity of 73% and a specificity of 100% 
in predicting the presence of a carcinoid in the midgut 
area  [33, 34] . However, chromogranin A is more sensitive, 
87%  [32] , and can signal recurrences early in patients 
with a small tumor burden  [35] . False positive chromo-
granin A levels can be found in patients medicating with 
proton pump inhibitors, atrophic gastritis, renal impair-
ment, or inflammatory bowel disease. 5-HIAA should be 
collected with strict dietary restrictions to avoid false 
positive levels.
 Minimal Consensus Statement on Laboratory Tests
 
 The minimally required biochemical tests include chromo-
granin A and HIAA. They should be performed at first visit and 
then for follow-up.
 After confirming the histopathological diagnosis, SRS 
with SPECT, which is positive in 80–90% of patients with 
small intestinal endocrine tumors, is a routine investiga-
tion for staging of the disease  [23] . It may detect the pri-
mary tumor or regional lymph node metastases and ad-
ditional metastatic lesions in the lung, breast, bone or 
brain. There are some limitations with regard to the spa-
tial resolution ( ! 1 cm) and negativity in lesions lacking 
the expression of sst2 and sst5. Recently, positron emis-
sion tomography (PET) with  68 Ga-labeled somatostatin 
analogs has been introduced as an alternative method in 
some centers  [24] .
 In case the patient presents both a primary tumor and 
liver metastases, a three-phase high-resolution CT or 
MRI with contrast enhancement, which are complemen-
tary procedures with a similar sensitivity in detecting en-
docrine lesions in the abdomen  [25–27] , should be per-
formed of positive areas to estimate the size of the lesions, 
determine the relationship to blood vessels, demonstrate 
surrounding desmoplastic reactions of mesenteric lymph 
nodes and primaries and, hence, judge the resectability 
of abdominal disease. A mesenteric tumor with radiating 
densities is considered pathognomonic for a mesenteric 
midgut metastasis.
 Whereas liver metastases are easily detected by US/
CT/MRI or SRS, localization of the primary within the 
distal small bowel may be difficult. Colonoscopy can 
identify primary tumors in the distal ileum or the ileoce-
cal valve. Barium enema or enteroclysis of the small in-
testine are rarely indicated. Instead new methods, such as 
capsule endoscopy or double balloon enteroscopy are 
promising.
 Standard PET with  18 F-deoxyglucose (FDG) is not ef-
ficient in well-differentiated endocrine tumors but re-
cently the use of PET with specific tracers for neuroen-
docrine tumors with  11 C-5-hydroxytryptophan (HTP) 
or  18 F-dihydroxyphenylalanine (DOPA) has shown 
promising results, particularly in classical midgut carci-
noid with sensitivities exceeding 90%  [28, 29] . PET with 
these tracers is better for detection of small primary tu-
mors and lymph node metastases than SRS or CT/
MRI.
 If bone metastases are indicated by SRS, MRI is rec-
ommended to estimate the tumor mass within the skel-
eton and indicate the risk of fractures. If SRS is negative, 
bone scan can be performed.
 Echocardiography is mandatory in patients with the 
carcinoid syndrome to confirm or exclude coexisting 
CHD and to judge the severity of the manifestation.
 Eriksson  et al.
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Surgery in patients with liver metastases
Resectable liver
metastases 
Unilobar or limited 
disease (20–25%)
Bilobar or complex
liver metastases 
(10–15%) 
Minor resection
(RFA) 
One-step surgery
Major liver resection
(RFA)
Two-step surgery
1. Minor resection (RFA)
2. Sequential major
hepatectomy
Unresectable liver
metastases  
Primary removed to focus on
Tx of LM
Multimodal Tx (60–70%) 
Liver transplantation
 (<1%)
Mortality <3%, morbidity <30%
 Pathology and Genetics
 Pathological diagnosis is mandatory in all cases and 
usually obtained on ultrasonography-guided liver biop-
sies or biopsies from surgery. Pathological diagnosis of 
jejunal-ileal tumors is achieved using hematoxylin-eosin 
staining, immunohistochemical staining with chromo-
granin A and synaptophysin  [36] . Determination of mi-
totic index and calculation of Ki-67 index by immunohis-
tochemistry is mandatory. The tumors should be classi-
fied according to the WHO system  [8] , knowing that the 
vast majority of tumors belong to WHO group 2.
 Minimal Consensus Statement on Pathology and 
Genetics
 
 Histopathology
 Histology is always necessary to establish diagnosis. Cytology 
may be helpful but is insufficient. The minimal ancillary tests to 
support the histological diagnosis include immunohistochem-
istry for chromogranin A, synaptophysin, and optionally sero-
tonin. Both the mitotic count in 10HPF (2 mm 2 , at least 40 fields 
(at 40 ! magnification) evaluated in areas of highest mitotic 
density, and the Ki-67 index (MIB1 antibody; % of 2,000 cells in 
areas of highest nuclear labeling)  [37] . The histopathology re-
port should allow for a correct classification according to the 
current WHO criteria. In the future, it should also provide in-
formation for a correct TNM-classification and grading (see be-
low). Immunohistochemistry for p53 and sst2 is not routinely 
recommended, with the exception of staining for sst2A if SRS is 
not available.
 Genetics
 Although a familiar clustering of midgut neuroendocrine tu-
mors  [38, 39] appears to exist, the genetic background has not 
been elucidated and there is no indication to perform genetic 
counseling, germline or somatic DNA testing.
 Summary of TNM Proposal
 A proposal for a TNM classification for tumors of the 
lower jejunum and ileum, where T1–4 describes size of 
the tumor (with T2 tumors  1 1 cm) and the depth of in-
volvement of the intestinal wall, was discussed. Stage I 
comprises T1 tumors with limited growth. Stage II iden-
tifies tumors that are larger in size or more invasive, i.e. 
T2 or T3, but without metastases. Stage III encompasses 
tumors invading surrounding structures (IIIa), T4, or the 
presence of regional lymph node metastases (IIIB), where-
as stage IV indicates distant metastases. In the proposal, 
a grading system is also included, in which the G1 tumor 
category has a mitotic count  ! 2 or Ki-67  ! 2%, G2 tumors 
a mitotic count 2–20 or Ki-67 2–20%, and G3 tumors mi-
totic count  1 20 or Ki-67  1 20%. The grading system and 
the WHO criteria are not exactly coherent with regard to 
mitotic count/Ki-67, since G3 tumors can belong to either 
 Fig. 2. Diagnostic algorithm for surgery in patients with liver metastases. 
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group 2 tumors (well-differentiated carcinoma) or group 
3 (poorly-differentiated carcinoma with Ki-67  1 30% ac-
cording to WHO). As a consequence of the proposal, the 
pathology report should include information about pro-
liferation index, immunohistochemistry for chromo-
granin A, synaptophysin, tumor diameter and invasion. 
With multiple lesions, the largest diameter should be re-
ported and for the N0 definition, a minimum of 12 lymph 
nodes should be assessed.
 Surgical Therapy ( fig. 2 )
 Curative Surgical Therapy
 Surgery of Localized Disease in Jejunal-Ileal Tumors. 
 Curative surgery should be aimed for in patients with en-
docrine tumors of the distal jejunum-ileum and localized 
disease. The size of the primary does not correspond to 
the metastatic propensity. Since tumor spread to lymph 
nodes and the liver can occur also in patients with small 
primary tumors, surgery of the primary should adhere to 
oncological principles. This involves clearance of lymph 
node metastases by dissection around the mesentery, 
aiming to preserve the vascular supply and to limit intes-
tinal resection  [40–45] .
 Surgery with Curative Intent of Jejunal-Ileal Carci-
noids Metastatic to the Liver.  Surgery has until now been 
therapy with a curative potential. Curative tumor resec-
tion, i.e. removal of the primary, regional lymph nodes, 
and resectable liver metastases, is possible in up to 20% 
of the patients  [42, 46, 47 , Ahlman, 2004, #369]. Liver 
surgery includes metastasis enucleation, segmental re-
section, hemihepatectomy or extended hemihepatecto-
my. Intraoperative ultrasonography should be per-
formed for detection of all liver metastases. Periopera-
tive mortality is  ! 3% in most reports and postoperative 
5-year survival rate is 61% and even higher in some cen-
ters  [46–53] . In contrast, in patients with midgut carci-
noids and with liver metastases without surgical thera-
py, recent publications report a 5-year survival rate of 
30% with a median survival of 3–4 years  [7, 46, 47, 51, 
54–57] . Curative intent in these studies was defined as 
the possibility of complete tumor resection. The com-
parison is, however, difficult, since most reports are 
from single institutions and no prospective randomized 
studies have been performed comparing medical thera-
py with surgery alone  [11] . As a prerequisite for these 
extended procedures, mortality should be  ! 5% and mor-
bidity  ! 30%.
 Minimal Consensus Statement on Curative Surgery
 
 Curative surgery is always recommended whenever feasible 
after careful symptomatic control of the clinical syndrome; the 
latter may be achieved by medical treatment (somatostatin ana-
logs, interferon). Surgery of the primary should be performed as 
segmental resection with wide lymphadenectomy. In case of 
lymph node involvement around the superior mesenteric artery, 
high lymph node dissection is recommended. In cases with se-
vere desmoplastic reaction around the artery, radical tumor re-
section may not be possible. Cholecystectomy is always recom-
mended. Tumor multicentricity, which may occur in 20% of all 
cases, demonstrated by SRS, CT, intraoperative palpation and/
or endoscopy, does not change the indication for surgery. The 
outcome of surgery may be worse in cases of distant metastases 
other than the liver, as in cases with the so-called frozen mesen-
teric root and peritoneal carcinomatosis. After curative surgery, 
there is no indication for medical therapy other than pre- and 
perioperative somatostatin analog treatment to avoid carcinoid 
crisis.
 Palliative Surgery
 Primary Tumor and Liver Metastases.  Cytoreductive 
surgery can be considered in all patients in whom 90% of 
the tumor can be safely removed  [49, 51, 53, 58] . Surgical 
intervention can be divided into resection of the primary 
with locoregional metastases or intraabdominal debulk-
ing, resection of liver metastases alone or synchronous 
resection of primary and liver metastases. Compared to 
patients with non-functional jejunal-ileal tumors, surviv-
al is reduced in patients with the carcinoid syndrome.
 Primary Tumors Excluding Liver Metastases.  Removal 
of the primary according to oncological criteria is indi-
cated to prevent intestinal obstruction or ischemic com-
plications due to a desmoplastic reaction of the mesente-
rium or compression of the mesenteric vein due to the 
tumor mass. As symptoms correlate with tumor mass, a 
reduction of tumor mass provides symptomatic relief in 
70–100% of the patients. Intra-abdominal tumor resec-
tion (liver excluded) increased survival significantly from 
69 to 130 months  [53, 58] . However, these data must be 
interpreted with caution, since surgery is mostly done in 
patients with less extensive disease and, in addition, most 
patients have received other therapies affecting the sur-
vival.
 Minimal Consensus Statement on Palliative Surgery
 
 Palliative surgery for patients with endocrine tumors of the 
jejunum-ileum has the objective to make liver metastases the 
only persisting problem. Patients suitable for palliative proce-
dures are those presumed to benefit from tumor reduction per-
formed in accordance with given guidelines. Palliative surgery 
should mainly be done for symptomatic reasons to facilitate for 
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other therapeutic modalities, i.e. medical and radioactive treat-
ment. The type of surgery should be individualized since no 
general approach can be given. If liver metastases require a mi-
nor resection, this can be done at the same procedure as the pri-
mary, otherwise it should be done in a second operation. In the 
palliative setting, medical therapy is usually required pre-, per-, 
and postoperatively.
 Medical Therapy
 Biotherapy
 Biotherapy is defined as a therapeutic modality con-
trolling hormonal hypersecretion syndromes and/or tu-
mor growth with substances or pharmacological analogs 
thereof, occurring naturally in the body. There are nu-
merous studies published in the literature, most of them 
with a small number of patients, but very few fulfill the 
criteria of evidence-based medicine, because of the low 
incidence of the tumor. Indeed, there are only a few stud-
ies on somatostatin analogs and none on interferon per-
formed in a randomized, prospective, multicenter fash-
ion, including patients with documented tumor progres-
sion.
 Somatostatin Analogs.  Somatostatin analogs effective-
ly reduce hypersecretion-related symptoms in patients 
with the carcinoid syndrome. The antisecretory effect re-
sults in a reduction of biochemical markers in up to 40–
60% and a symptomatic improvement in 40–80% of pa-
tients  [59–72] . The duration of the effect varies and can 
be limited due to tachyphylaxis or desensitization, which 
can be temporarily circumvented by an increase in dose. 
The antiproliferative effect of somatostatin analogs is 
modest, and partial or complete responses can be ob-
served in fewer than 10% of the patients. However, stabi-
lization of tumor growth occurs in 24–57% of patients 
with documented tumor progression before start of so-
matostatin analog therapy  [62, 63, 70, 73, 74] . Hence, so-
matostatin analogs are clearly indicated for symptomatic 
relief in functioning jejunal-ileal endocrine tumors. Tol-
erance to somatostatin analogs and efficacy should be 
tested individually by initiating therapy with short-act-
ing analogs. Thereafter, depot formulations, usually oc-
treotide-LAR (20–30 mg) or Lanreotide Autogel every 4 
weeks can be started and should be individually titrated. 
The efficacy of lanreotide and octreotide is comparable 
 [65, 66, 70] . Minor initial side effects include abdominal 
discomfort, flatulence, and sometimes steatorrhea that 
usually subside  [61, 66, 67, 75] . In patients with steator-
rhea, pancreatic enzyme replacement can help. More 
than 50% of patients have been reported to develop gall-
stones, however, virtually all remain asymptomatic  [75] . 
To prevent carcinoid crisis, somatostatin analogs should 
be given intravenously during anesthesia or other inter-
ventional procedures. Loperamide and morphine ana-
logs may improve secretory diarrhea. Since diarrhea may 
have other causes than hormonal (bile acid loss, bacterial 
overgrowth) other options may be considered, such as 
cholestyramine and antibiotics.
 Minimal Consensus Statement on Somatostatin 
Analogs
 
 Somatostatin analog therapy is recommended as first-line 
medical treatment in functioning tumors. It provides symptom-
atic improvement in 70–80% of patients and stabilization of tu-
mor growth in up to 50% of patients with varying duration. 
Whether somatostatin analogs should be used in non-function-
ing tumors is not established but ongoing studies should clarify 
this issue. SRS-positive tumors tend to respond better than SRS-
negative tumors. At least one study on lanreotide-PR showed 
that quality of life was improved by treatment  [61] but there is 
no apparent relation to the dose of somatostatin analogs.
 
 
 As mentioned before, cholecystectomy is recommend-
ed during abdominal surgery to prevent the development 
of gallstones.
 Steatorrhea may lead to malabsorption of vitamin D 
with reduced calcium absorption  [75] . Patients on soma-
tostatin analogs should also have vitamin B 12  levels mon-
itored, since these levels may be reduced possibly due to 
inhibition of intrinsic factor. To control diarrhea, loper-
amide, cholestyramine (after ileocecal/ileal resection) or 
pancreatic enzyme substitution may be necessary.
 Interferon.  Interferon-  is given for the same indication 
as somatostatin analogs, with the exception of carcinoid 
crisis. Its effect on symptom control, though not as rapid, 
is comparable to somatostatin analogs. A biochemical and 
symptomatic response could be noted in up to 50% of pa-
tients, whereas partial tumor size responses could be dem-
onstrated in 10–15%  [76–87] . The duration of response was 
12–36 months. Due to more pronounced side effects, in-
terferon is generally used as second-line therapy for symp-
tomatic control. Interferon, usually recombinant interfer-
on-  , is given subcutaneously at 3–5 MU 3–5 times a week. 
A pegylated formulation, i.e. long-acting given once a 
week, is available but not yet registered. Minor side effects 
include flu-like symptoms (relieved by paracetamol), 
weight loss and fatigue. Major side effects include autoim-
mune reactions, depression and mental disturbances. Bone 
marrow toxicity is usually mild as is hepatotoxicity, which 
can be managed by dose adjustments.
 Well-Differentiated Jejunal-Ileal
Tumor/Carcinoma 
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 Minimal Consensus Statement on Interferon 
Treatment
 
 Interferon treatment is recommended as second-line treat-
ment of functioning tumors of the jejunum-ileum with a low 
proliferation rate. The dose should be individually titrated ac-
cording to the leukocyte count and given at night for better tol-
erance. Similarly to somatostatin analogs the use of interferon 
in non-functioning tumors is not established, but future trials 
may clarify this issue.
 
 Whether the combination of somatostatin analogs 
and interferon is more effective than the single drugs has 
not been established  [70, 88–90] but patients progressing 
on monotherapy of either drug may benefit from the 
 addition of the other drug. As adjuncts to control diar-
rhea, loperamide, cholestyramine (after ileocecal/ileal 
resection) or pancreatic enzyme substitution may be in-
dicated.
 Chemotherapy
 The results with systemic chemotherapy have been 
poor in patients with jejunal-ileal endocrine tumors. 
 Single agents (5-FU, doxorubicin, DTIC) and combina-
tions (streptozotocin + doxorubicin or 5-fluorouracil) 
generally produce responses in  ! 15% of patients  [15, 17, 
91–93] .
 Minimal Consensus Statement on Chemotherapy
 
 There is a general consensus that chemotherapy with agents 
available today is not recommended in this patient category. The 
only exception represents poorly-differentiated carcinomas.
 Peptide Receptor Radionuclide Therapy
 Most endocrine jejunal-ileal tumors express soma-
tostatin receptors, especially subtype 2 (sst2). Targeting 
these receptors with radiolabeled somatostatin analogs 
may not only be used for imaging but also for radiother-
apy. Since the early 1990s, different radiolabeled analogs 
have been used for tumor-targeted therapy  [94–97] . For 
metastatic disease with evidence of expression of sst2 as 
demonstrated by SRS, two still FDA- and EMEA-un-
approved analogs for peptide receptor radionuclide ther-
apy (PRRT) –  90 Y-DOTA-octreotide  [98–109] and  177 Lu-
DOTA-octreotate (Lutate)  [110–113] – show promising 
results. Phase I–II trials have shown symptomatic im-
provement in advanced cases of neuroendocrine tumors. 
Partial and minor responses and stabilization in patients 
with progressive disease at the start of treatment occurred 
in 12–35, 12–14, and 28–56%, respectively. The most re-
cent data indicate PR or CR in 28% of patients with a me-
dian time to progression of more than 36 months for Lu-
tate  [114] .
 These radiopharmaceuticals are only available in a few 
centers. The treatment has to be performed in collabora-
tion with nuclear medicine units. Side effects are limited 
as long as radiation dose to the kidney and bone marrow 
are kept within dose limits; the use of kidney protection 
by co-infusion of amino acids (lysine and arginine) al-
lows the administration of higher doses of the radiophar-
maceuticals.
 Minimal Consensus Statement on PRRT
 
 PRRT is recommended in SRS-positive tumors in symptom-
atic patients refractory to medical treatment with inoperable 
disease.  90 Y- or  177 Lu-coupled analogs should be employed.
 Carcinoid Heart Disease
 CHD develops in 40–50% of patients with the carci-
noid syndrome  [19, 20] and has been described to be the 
cause of death in 30–50% of patients  [20, 21] . It is charac-
terized by plaque-like, fibrous endocardial thickening 
that principally involves the right side of the heart, caus-
ing retraction and fixation of the leaflets of the tricuspid 
and pulmonary valves as well as diminished right ven-
tricular function  [115] . Tricuspid regurgitation is a near-
ly universal finding. These valvular lesions will eventu-
ally lead to right-sided heart failure. The pathogenesis of 
the fibrosis in the right side of the heart has now been 
partly clarified by Gustafsson et al.  [116] , showing that 
serotonin plays a role. Several earlier studies have shown 
that HIAA and tachykinins are higher in those patients 
with CHD than in those without it  [20] .
 Screening for CHD should be performed on a regular 
basis. If it develops, heart failure rather than metastatic 
disease may be the cause of death. Medical therapy for 
heart failure should be introduced when necessary and 
cardiac surgery with valve replacement (bioprosthesis) 
should be considered for patients, in whom control of 
hormonal symptoms and tumor growth has been 
achieved. Cardiac surgery should be performed before 
major liver surgery or liver embolization.
 Eriksson  et al.
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 Minimal Consensus Statement on Carcinoid Heart 
Disease
 
 For patients with the carcinoid syndrome and CHD, trans-
thoracic echocardiography should be performed annually. For 
timing of cardiac surgery with replacement of the tricuspid (and 
pulmonary) valves, brain natriuretic peptide measurements 
may be helpful, since they reflect the load on the right side of the 
heart  [117] . The decision should be made in collaboration with 
an experienced cardiologist.
 Follow-Up
 For patients having undergone surgery with a curative 
intent, the schedule for follow-up should be every 6–12 
months, with the exception of grade 3 tumors, which 
should be followed every 3 months. Minimal examina-
tions include measurement of chromogranin A and 5-
HIAA and three-phasic CT. SRS should be done in sus-
pected recurrences before any therapeutic decisions are 
made. The follow-up should be lifelong considering the 
epidemiological data indicating that after 25 years only 
23% of patients are free of disease  [15] .
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